Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Popular Filters
Trials for CCA Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for Bile Duct Cancer Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for FGFR2 Positive Patients
Tyrosine Kinase Inhibitor
RLY-4008 for Bile Duct Cancer
This trial is testing a new drug called RLY-4008 in patients with hard-to-treat cancers that can't be removed by surgery or have spread. The drug works by blocking a protein that helps cancer cells grow.
Tyrosine Kinase Inhibitor
Afatinib + Pemigatinib for Solid Tumors
This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Trials for IDH Positive Patients
PARP Inhibitor
Olaparib for Advanced Cancer
This trial will study how well olaparib works in treating patients with certain types of cancer that have spread and usually cannot be controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase 3 Trials
Monoclonal Antibodies
CTX-009 + Paclitaxel for Biliary Tract Cancer
This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Alkylating agents
Chemotherapy for Biliary Tract Cancer
This trial is testing how well two cancer-fighting drugs work together, and whether adding a third drug makes them more effective in treating patients with advanced biliary tract cancers. The drugs aim to kill cancer cells, stop them from dividing, or prevent them from spreading.
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Trials With No Placebo
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
View More Related Trials
Frequently Asked Questions
Introduction to intrahepatic cholangiocarcinoma
What are the top hospitals conducting intrahepatic cholangiocarcinoma research?
Intrahepatic cholangiocarcinoma, a rare and aggressive form of liver cancer, has spurred renowned hospitals across the United States to conduct groundbreaking clinical trials in search of effective treatments. Memorial Sloan Kettering Cancer Center in New york leads the charge with 13 active trials dedicated to this condition and a cumulative total of 25 trials since their first recorded exploration in 2000. Meanwhile, Massachusetts General Hospital in Boston follows closely behind with nine ongoing intrahepatic cholangiocarcinoma trials and an impressive history of 19 previous studies dating back to their inaugural trial in 2006.
The University of Texas MD Anderson Cancer Center, located in Houston, is also playing a significant role by conducting eight active clinical trials for intrahepatic cholangiocarcinoma. Their commitment to research began more recently with their first recorded trial occurring just seven years ago in 2014. Additionally, another institution within the MD Anderson network joins the fight against this challenging disease as they too have conducted eight active clinical tests alongside fifteen past investigations since initiating their pioneering study on intrahepatic cholangiocarcinoma starting from 2011.
Lastly but not leastly; yet another branch from M D Anderson Cancer Center based out at Houston has made its own mark by actively spearheading six current explorations while carrying out sixteen former efforts after taking initiative commencing only around decade ago,in year2014to broaden horizons for such patients battling against Intraheptic Chlangocarcoma
These esteemed hospitals are at the forefront of cutting-edge research into finding better treatment options for those affected by intrahepatic cholangiocarcinoma. With each new trial and every breakthrough discovery, we move one step closer towards improving outcomes and offering hope to individuals facing this formidable disease.
Which are the best cities for intrahepatic cholangiocarcinoma clinical trials?
When it comes to clinical trials for intrahepatic cholangiocarcinoma, several cities in the United States are leading the way. Houston, Texas stands out with 37 active trials, investigating treatments like NGM831 and RLY-4008. New york City and Boston tie at 32 active trials each, exploring options such as gavo-cel and Cobimetinib respectively. Los Angeles, California follows closely behind with 26 ongoing studies focused on Nivolumab and pembrolizumab among others. While Anchorage, Alaska also has 26 active trials underway examining treatments like Arm B (pevonedistat, paclitaxel, carboplatin) and Cisplatin. These cities offer individuals diagnosed with intrahepatic cholangiocarcinoma access to cutting-edge clinical research that may lead to better treatment outcomes and improved quality of life.
Which are the top treatments for intrahepatic cholangiocarcinoma being explored in clinical trials?
Clinical trials are exploring various treatments to combat intrahepatic cholangiocarcinoma, a challenging form of cancer. Among the leading contenders are gemcitabine, having 5 active and 51 all-time trials since its introduction in 2002; durvalumab with 2 ongoing and a total of 16 clinical trials for this specific type of cancer since it first appeared in 2016; tivozanib, a newcomer with two current studies and two overall trials dedicated to intrahepatic cholangiocarcinoma starting from its listing in 2021; and olaparib, also involved in two active trials out of five cumulative investigations focused on this disease since being listed as a potential treatment option in 2019. These advancements offer hope for patients battling intrahepatic cholangiocarcinoma.
What are the most recent clinical trials for intrahepatic cholangiocarcinoma?
Exciting advancements are underway in the field of intrahepatic cholangiocarcinoma, with recent clinical trials offering promising prospects for patients. One notable trial is evaluating the efficacy of Tinengotinib 8 mg QD as a potential treatment option in Phase 3. Additionally, Phase 2 trials are exploring various approaches such as Arm A and Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy to address this challenging cancer type. These studies aim to uncover new strategies and therapeutic combinations that may significantly improve outcomes for individuals battling intrahepatic cholangiocarcinoma.
What intrahepatic cholangiocarcinoma clinical trials were recently completed?
Several clinical trials exploring innovative treatments for intrahepatic cholangiocarcinoma have recently concluded, signifying important progress in the field. In August 2020, Celldex Therapeutics completed a trial investigating CDX-527's potential as a targeted therapy. Similarly, the National Cancer Institute wrapped up their study on MVT-5873 in November 2019. Mayo Clinic also contributed to this research by completing a trial on Trifluridine and Tipiracil Hydrochloride in October 2019. These advancements underscore the commitment of researchers to finding new approaches to combatting intrahepatic cholangiocarcinoma and bring hope to patients facing this challenging disease.